ZA200606615B - Heteroaryl-fused pyrazolo derivatives - Google Patents

Heteroaryl-fused pyrazolo derivatives

Info

Publication number
ZA200606615B
ZA200606615B ZA200606615A ZA200606615A ZA200606615B ZA 200606615 B ZA200606615 B ZA 200606615B ZA 200606615 A ZA200606615 A ZA 200606615A ZA 200606615 A ZA200606615 A ZA 200606615A ZA 200606615 B ZA200606615 B ZA 200606615B
Authority
ZA
South Africa
Prior art keywords
heteroaryl
pyrazolo derivatives
fused pyrazolo
fused
derivatives
Prior art date
Application number
ZA200606615A
Other languages
English (en)
Inventor
Mccaleb Kristen Lynn
Roland J Billedeau
Gabriel Tobias
Soth Michael
Arora Nidhi
Dewdney Nolan James
Goldstein David Michael
Trejo-Martin Teresa Alejandra
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ZA200606615B publication Critical patent/ZA200606615B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
ZA200606615A 2004-02-27 2006-08-08 Heteroaryl-fused pyrazolo derivatives ZA200606615B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54864204P 2004-02-27 2004-02-27

Publications (1)

Publication Number Publication Date
ZA200606615B true ZA200606615B (en) 2008-02-27

Family

ID=34919387

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200606615A ZA200606615B (en) 2004-02-27 2006-08-08 Heteroaryl-fused pyrazolo derivatives

Country Status (16)

Country Link
US (1) US7452880B2 (xx)
EP (1) EP1720878A1 (xx)
JP (1) JP2007523936A (xx)
KR (1) KR100844864B1 (xx)
CN (1) CN1934111A (xx)
AR (1) AR048069A1 (xx)
AU (1) AU2005219517A1 (xx)
BR (1) BRPI0508220A (xx)
CA (1) CA2558109A1 (xx)
IL (1) IL177259A0 (xx)
MX (1) MXPA06009462A (xx)
NO (1) NO20064000L (xx)
RU (1) RU2006134021A (xx)
TW (1) TW200533671A (xx)
WO (1) WO2005085248A1 (xx)
ZA (1) ZA200606615B (xx)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2537916A1 (en) * 2003-09-03 2005-03-31 Neurogen Corporation 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
BRPI0508036A (pt) * 2004-02-27 2007-07-17 Hoffmann La Roche derivados fundidos de pirazola
MXPA06009462A (es) 2004-02-27 2007-03-15 Hoffmann La Roche Derivados pirazolo heteroaril fusionados.
US7405220B2 (en) * 2004-06-09 2008-07-29 Hoffmann-La Roche Inc. Pyrazolopyrimidines
MX2007006103A (es) 2004-11-22 2007-07-20 Vertex Pharma Pirrolopirazinas y pirazolopirazinas de utilidad como inhibidores de proteinquinasas.
GB0427604D0 (en) * 2004-12-16 2005-01-19 Novartis Ag Organic compounds
AR057455A1 (es) * 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
BRPI0615270A2 (pt) * 2005-08-25 2009-08-04 Hoffmann La Roche pirazol fundido como inibidores de p38 map cinase
MX2008002588A (es) * 2005-08-25 2008-03-18 Hoffmann La Roche Inhibidores de p38-map-cinasa y los metodos para utilizarlos.
DE102006029074A1 (de) * 2006-06-22 2007-12-27 Friedrich-Schiller-Universität Jena 4-Amino-3-arylamino-6-arylpyrazolo[3,4-d]pyrimidin-Derivate, Verfahren zu ihrer Herstellung und deren Verwendung als antivirale Wirkstoffe
TW200831085A (en) * 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
EP2091952A1 (en) 2006-12-19 2009-08-26 F. Hoffmann-Roche AG Pyrazolo ý3, 4 -d¨pyrimidine p38 map kinase inhibitors
WO2008104473A2 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Pyrazolopyriidine derivatives and their use as kinase inhibitors
WO2008112695A2 (en) * 2007-03-12 2008-09-18 Irm Llc Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment
US20110160232A1 (en) 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
WO2009114870A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Kinase inhibitors and methods of use
CN104530052A (zh) * 2008-06-10 2015-04-22 普莱希科公司 用于激酶调节的5h-吡咯[2,3-b]吡嗪衍生物和其适应症
US9096611B2 (en) 2008-07-08 2015-08-04 Intellikine Llc Kinase inhibitors and methods of use
US8220787B2 (en) * 2008-09-19 2012-07-17 Panasonic Corporation Part mounting device
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
WO2010111527A1 (en) * 2009-03-26 2010-09-30 Plexxikon, Inc. Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use
GEP201706639B (en) 2009-08-17 2017-03-27 Intellikine Llc Heterocyclic compounds and uses thereof
WO2011049988A2 (en) * 2009-10-20 2011-04-28 Eiger Biopharmaceuticals, Inc. Indazoles to treat flaviviridae virus infection
JP2013518113A (ja) * 2010-01-27 2013-05-20 バーテックス ファーマシューティカルズ インコーポレイテッド ピラゾロピラジンキナーゼ阻害剤
AU2011337041B2 (en) 2010-12-02 2015-05-14 Eli Lilly And Company 3-substituted-6-(pyridinylmethoxy)-pyrrolopyridine compounds
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US8362023B2 (en) 2011-01-19 2013-01-29 Hoffmann-La Roche Inc. Pyrazolo pyrimidines
TWI592411B (zh) 2011-02-23 2017-07-21 英特爾立秦有限責任公司 激酶抑制劑之組合及其用途
US11466017B2 (en) 2011-03-10 2022-10-11 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of PTPN11
HUE033019T2 (en) * 2011-05-17 2017-11-28 Principia Biopharma Inc Tyrosine kinase inhibitors
WO2013138613A1 (en) 2012-03-16 2013-09-19 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
ME03300B (me) 2012-06-13 2019-07-20 Incyte Holdings Corp Supsтituisana triciklična jedinjenja као inhibiтori fgfr
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
CA2907726A1 (en) 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc1/2 inhibitors and selective inhibitors of aurora a kinase
ME03015B (me) 2013-04-19 2018-10-20 Incyte Holdings Corp Biciklični heterocikli kao fgfr inhibitori
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CN105622613B (zh) * 2014-11-14 2019-03-12 安礼特（上海）医药科技有限公司 一种合成伊鲁替尼的方法
ES2805528T3 (es) 2014-12-23 2021-02-12 Sma Therapeutics Inc Inhibidores de 3,5-diaminopirazol quinasa
MA51229A (fr) 2015-02-20 2021-03-24 Incyte Corp Hétérocycles bicycliques utilisés comme inhibiteurs des fgfr
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
WO2017210134A1 (en) 2016-05-31 2017-12-07 Board Of Regents, University Of Texas System Heterocyclic inhibitors of ptpn11
US20180072741A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
WO2018049191A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridone derivatives as hpk1 modulators and uses thereof for the treatment of cancer
IL292977A (en) 2016-09-09 2022-07-01 Incyte Corp Pyrazolopyridine derivatives as modulators of hpk1 and their use in cancer therapy
WO2018152220A1 (en) 2017-02-15 2018-08-23 Incyte Corporation Pyrazolopyridine compounds and uses thereof
CN108570052A (zh) * 2017-03-13 2018-09-25 中国科学院上海药物研究所 五元杂环并吡嗪化合物、制备方法、中间体、组合和应用
RU2638928C1 (ru) * 2017-04-03 2017-12-19 федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургская государственная химико-фармацевтическая академия" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПХФА Минздрава России) Производные 1Н-пиразоло[3,4-d]пиримидина и способ их получения
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2019051199A1 (en) 2017-09-08 2019-03-14 Incyte Corporation 6-CYANO-INDAZOLE COMPOUNDS AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CA3128468A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
MX2020008656A (es) 2018-02-20 2020-12-09 Incyte Corp Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores de la cinasa de progenitores hematopoyeticos 1 (hpk1) para tratar el cancer.
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
WO2019213318A1 (en) * 2018-05-02 2019-11-07 Board Of Regents, The University Of Texas System Substituted heterocyclic inhibitors of ptpn11
MX2020011639A (es) 2018-05-04 2021-02-15 Incyte Corp Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr).
IL312465A (en) 2018-05-04 2024-06-01 Incyte Corp FGFR inhibitor solid forms and processes for their preparation
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
DK3833670T3 (da) 2018-08-10 2024-05-13 Navire Pharma Inc 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorphenyl)-2-methylpyrimidin-4(3h)-on-derivater og lignende forbindelser som PTPN11- (SHP2) hæmmere til cancerbehandling
EP3856348B1 (en) 2018-09-25 2024-01-03 Incyte Corporation Pyrazolo[4,3-d]pyrimidine compounds as alk2 and/or fgfr modulators
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
CN110343103A (zh) * 2019-07-04 2019-10-18 深圳市格物致欣化学技术有限公司 吡唑并吡啶类化合物及其制备方法
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11066394B2 (en) 2019-08-06 2021-07-20 Incyte Corporation Solid forms of an HPK1 inhibitor
EP4045151A1 (en) 2019-10-14 2022-08-24 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
MX2022006691A (es) 2019-12-04 2022-09-19 Incyte Corp Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr).
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
KR20230107802A (ko) * 2020-09-30 2023-07-18 에프엘2022-001, 인코포레이티드 Hsd17b13 억제제 및 이의 용도
TW202313611A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之三環雜環

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB937725A (en) * 1960-05-11 1963-09-25 Ciba Ltd Pyrazolo[3:4-d]pyrimidines
BE758050A (fr) 1969-10-28 1971-04-27 Geigy Ag J R Derives 5-nitro-furyliques et medicaments contenant de tels composes
US3821382A (en) * 1969-10-28 1974-06-28 Ciba Geigy Corp 5-nitrofuryl derivatives as antibacterial agents
CA933919A (en) * 1970-09-09 1973-09-18 Ciba-Geigy Corporation Process for the production of new 5-nitrofuryl derivatives
US3948913A (en) * 1971-04-27 1976-04-06 Ciba-Geigy Corporation New 5-nitrofuryl derivatives
DE2430454A1 (de) * 1974-06-25 1976-01-15 Thomae Gmbh Dr K Neue pyrazolo eckige klammer auf 3,4d eckige klammer zu pyrimidine
US4044130A (en) * 1974-07-03 1977-08-23 Ciba-Geigy Corporation Compositions for the control of microorganisms
US4020072A (en) * 1976-05-04 1977-04-26 E. R. Squibb & Sons, Inc. 5-Aminomethyl-1H-pyrazolo[3,4-b]pyridines
US4260505A (en) * 1978-10-25 1981-04-07 Olin Corporation Tris-(polyalkoxyalkylated) isocyanurate compounds and their use as functional fluids
IT1154024B (it) 1982-09-22 1987-01-21 Lepetit Spa Derivati pridinici e procedimento per la loro produzione
US5763597A (en) * 1989-09-15 1998-06-09 Metabasis Therapeutics, Inc. Orally active adenosine kinase inhibitors
US5656629A (en) * 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
NZ334213A (en) 1996-09-04 2000-08-25 Pfizer Indazole derivatives as inhibitors of phosphodiesterase (PDE) type IV and the production of tumor necrosis factor (TNF) for treating asthma, arthritis, bronchitis, CNS disorders
DE19709877A1 (de) * 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
HUP0004150A3 (en) 1997-11-04 2001-08-28 Pfizer Prod Inc Indazole derivatives as tyrosine kinase receptor antagonists and pharmaceutical compositions containing them
US6531477B1 (en) * 1998-10-13 2003-03-11 Dupont Pharmaceuticals Company 6-substituted pyrazolo [3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
AU1818400A (en) 1998-11-12 2000-05-29 Eli Lilly And Company Aryloxime linkers in the solid-phase synthesis of 3-aminobenzisoxazoles
ATE310733T1 (de) 2000-04-21 2005-12-15 Pfizer Prod Inc Thyroid-rezeptorliganden
AU2001264313A1 (en) 2000-06-20 2002-01-02 Japan Tobacco Inc. Pyrazolopyridine compounds and use thereof as drugs
DE10046029A1 (de) 2000-09-18 2002-03-28 Bayer Ag Indazole
DK1355904T3 (da) 2000-12-22 2007-10-15 Wyeth Corp Heterocyclindazol- og -azaindazolforbindelser som 5-hydroxytryptamin-6-ligander
TW593278B (en) 2001-01-23 2004-06-21 Wyeth Corp 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
US20030114467A1 (en) 2001-06-21 2003-06-19 Shakespeare William C. Novel pyrazolo- and pyrrolo-pyrimidines and uses thereof
WO2003063764A2 (en) * 2001-07-10 2003-08-07 Bristol-Myers Squibb Pharma Company 6-SUBSTITUTED PYRAZOLO [3,4-d] PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS
US20040235867A1 (en) 2001-07-24 2004-11-25 Bilodeau Mark T. Tyrosine kinase inhibitors
JP4459619B2 (ja) * 2001-10-02 2010-04-28 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 化合物
AU2003214873A1 (en) 2002-01-18 2003-09-02 Ceretek Llc Methods of treating conditions associated with an edg receptor
TW200302722A (en) 2002-02-13 2003-08-16 Astrazeneca Ab Therapeutic agents
BR0308232A (pt) * 2002-03-07 2004-12-28 Hoffmann La Roche Inibidores de cinase p38 de piridina e pirimidina bicìclicas
TW200400034A (en) * 2002-05-20 2004-01-01 Bristol Myers Squibb Co Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
CA2495216A1 (en) * 2002-08-12 2004-02-19 Sugen, Inc. 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
AU2004218463B2 (en) 2003-03-03 2009-07-16 Array Biopharma, Inc. p38 inhibitors and methods of use thereof
DE102004006767B4 (de) * 2004-02-11 2011-06-30 Infineon Technologies AG, 81669 Verfahren und Vorrichtung zum Transport von Datenabschnitten mittels eines DMA-Controllers
BRPI0508036A (pt) * 2004-02-27 2007-07-17 Hoffmann La Roche derivados fundidos de pirazola
MXPA06009462A (es) 2004-02-27 2007-03-15 Hoffmann La Roche Derivados pirazolo heteroaril fusionados.
US7405220B2 (en) * 2004-06-09 2008-07-29 Hoffmann-La Roche Inc. Pyrazolopyrimidines

Also Published As

Publication number Publication date
RU2006134021A (ru) 2008-04-10
JP2007523936A (ja) 2007-08-23
BRPI0508220A (pt) 2007-07-17
AU2005219517A1 (en) 2005-09-15
TW200533671A (en) 2005-10-16
WO2005085248A1 (en) 2005-09-15
EP1720878A1 (en) 2006-11-15
KR20060117359A (ko) 2006-11-16
IL177259A0 (en) 2006-12-10
US20050203091A1 (en) 2005-09-15
CA2558109A1 (en) 2005-09-15
CN1934111A (zh) 2007-03-21
NO20064000L (no) 2006-09-22
AR048069A1 (es) 2006-03-29
US7452880B2 (en) 2008-11-18
MXPA06009462A (es) 2007-03-15
KR100844864B1 (ko) 2008-07-09

Similar Documents

Publication Publication Date Title
ZA200606615B (en) Heteroaryl-fused pyrazolo derivatives
TWI369356B (en) Tetrahydropyridoindole derivatives
IL180481A0 (en) Aryl-pyridine derivatives
ZA200610102B (en) Pyrrazolo-pyrimidine derivatives
IL177510A0 (en) Pyrazolopyrimidines
IL183140A0 (en) Substituted benzoquinolizine derivatives
IL172098A0 (en) Triazolopyrimidines
ZA200703172B (en) Imidazo-benzodiazepine derivatives
IL177204A0 (en) Novel 4-benzimidazol -2-ylpyridazin -3- one derivatives
ZA200510276B (en) Triazolopyrimidines
HK1100002A1 (en) 4-phenyl-pyrimidine-2-carbonitrile derivatives
IL182739A0 (en) Acylatednonadepsipeptides used as lysobactin derivatives
HK1120803A1 (en) Pyrazolo
HK1100775A1 (en) 4-Amino-5-cyanopyrimidine derivatives
GB0414272D0 (en) OsK1 derivatives
IL182001A0 (en) 2-acylaminothiazole derivatives
GB0400945D0 (en) The bugcap
GB0411078D0 (en) Bicyclic derivatives
GB0417522D0 (en) The complex cube
GB0422398D0 (en) Pyridopyrimidine derivatives
GB0422395D0 (en) Pyrimidopyrimidine derivatives
GB0405905D0 (en) Azaquinazoline derivatives
GB0422397D0 (en) 3-Cyano-Quinoline derivatives
GB0407464D0 (en) Beacon
AU2004903691A0 (en) Pyrazolopyridine Derivatives